Cargando…

The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma

BACKGROUND AND PURPOSE: Carbon ion (C-ion) beams are concentrated to irradiate pancreatic carcinoma in the upper abdomen; however, this radiotherapy potentially causes adverse reactions in the gastrointestinal tract. FGF1 is a candidate radioprotector for radiation-induced intestinal damage, but may...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawano, Mitsuko, Miura, Taichi, Fujita, Mayumi, Koike, Sachiko, Imadome, Kaori, Ishikawa, Atsuko, Yasuda, Takeshi, Imamura, Toru, Imai, Takashi, Nakayama, Fumiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215021/
https://www.ncbi.nlm.nih.gov/pubmed/30406211
http://dx.doi.org/10.1016/j.ctro.2018.10.004
_version_ 1783368061535911936
author Kawano, Mitsuko
Miura, Taichi
Fujita, Mayumi
Koike, Sachiko
Imadome, Kaori
Ishikawa, Atsuko
Yasuda, Takeshi
Imamura, Toru
Imai, Takashi
Nakayama, Fumiaki
author_facet Kawano, Mitsuko
Miura, Taichi
Fujita, Mayumi
Koike, Sachiko
Imadome, Kaori
Ishikawa, Atsuko
Yasuda, Takeshi
Imamura, Toru
Imai, Takashi
Nakayama, Fumiaki
author_sort Kawano, Mitsuko
collection PubMed
description BACKGROUND AND PURPOSE: Carbon ion (C-ion) beams are concentrated to irradiate pancreatic carcinoma in the upper abdomen; however, this radiotherapy potentially causes adverse reactions in the gastrointestinal tract. FGF1 is a candidate radioprotector for radiation-induced intestinal damage, but may promote the malignancy of pancreatic cancer. An FGF1/CPP-C chimeric protein was created to enhance the intracellular signaling mode of FGF1 instead of FGFR signaling. The present study investigated the effects of FGF1/CPP-C on the intestinal adverse reactions of C-ion radiotherapy as well as its influence on the malignancy of pancreatic cancer. MATERIALS AND METHODS: FGF1/CPP-C was administered intraperitoneally to BALB/c mice without heparin 12 h before total body irradiation (TBI) with low-LET C-ion (17 keV/μm) at 6–8 Gy. Several radioprotective effects were examined in the jejunum. The invasion and migration of the human pancreatic carcinoma cell lines MIAPaCa-2 and PANC-1 were assessed using Boyden chambers after cultures with FGF1/CPP-C. RESULTS: The FGF1/CPP-C treatment promoted crypt survival after C-ion irradiation at 7–8 Gy significantly more than the FGF1 treatment. FGF1/CPP-C also inhibited C-ion radiotherapy-induced apoptosis and reduced γH2AX foci in crypt cells more than FGF1. However, FGF1/CPP-C inhibited the downstream signaling pathways of FGFRs and suppressed the activation of cell-cycle regulatory molecules in the intestine until 4 h after TBI. Furthermore, IEC6 cells were arrested in G2M after cultures with FGF1/CPP-C or FGF1, suggesting that DNA repair after irradiation is promoted by FGF1/CPP-C-induced G2M arrest. In contrast, FGF1/CPP-C appeared to be internalized into MIAPaCa-2 and PANC-1 cells more efficiently than FGF1. Therefore, FGF1/CPP-C reduced the in vitro proliferation, invasion, and migration of MIAPaCa-2 and PANC-1 cells significantly more than FGF1 through the cellular internalization of FGF1. CONCLUSION: These results suggest that the intracellular signaling mode of FGF1/CPP-C attenuates the intestinal adverse effects of C-ion radiotherapy without enhancing the malignancy of pancreatic carcinoma.
format Online
Article
Text
id pubmed-6215021
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-62150212018-11-07 The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma Kawano, Mitsuko Miura, Taichi Fujita, Mayumi Koike, Sachiko Imadome, Kaori Ishikawa, Atsuko Yasuda, Takeshi Imamura, Toru Imai, Takashi Nakayama, Fumiaki Clin Transl Radiat Oncol Article BACKGROUND AND PURPOSE: Carbon ion (C-ion) beams are concentrated to irradiate pancreatic carcinoma in the upper abdomen; however, this radiotherapy potentially causes adverse reactions in the gastrointestinal tract. FGF1 is a candidate radioprotector for radiation-induced intestinal damage, but may promote the malignancy of pancreatic cancer. An FGF1/CPP-C chimeric protein was created to enhance the intracellular signaling mode of FGF1 instead of FGFR signaling. The present study investigated the effects of FGF1/CPP-C on the intestinal adverse reactions of C-ion radiotherapy as well as its influence on the malignancy of pancreatic cancer. MATERIALS AND METHODS: FGF1/CPP-C was administered intraperitoneally to BALB/c mice without heparin 12 h before total body irradiation (TBI) with low-LET C-ion (17 keV/μm) at 6–8 Gy. Several radioprotective effects were examined in the jejunum. The invasion and migration of the human pancreatic carcinoma cell lines MIAPaCa-2 and PANC-1 were assessed using Boyden chambers after cultures with FGF1/CPP-C. RESULTS: The FGF1/CPP-C treatment promoted crypt survival after C-ion irradiation at 7–8 Gy significantly more than the FGF1 treatment. FGF1/CPP-C also inhibited C-ion radiotherapy-induced apoptosis and reduced γH2AX foci in crypt cells more than FGF1. However, FGF1/CPP-C inhibited the downstream signaling pathways of FGFRs and suppressed the activation of cell-cycle regulatory molecules in the intestine until 4 h after TBI. Furthermore, IEC6 cells were arrested in G2M after cultures with FGF1/CPP-C or FGF1, suggesting that DNA repair after irradiation is promoted by FGF1/CPP-C-induced G2M arrest. In contrast, FGF1/CPP-C appeared to be internalized into MIAPaCa-2 and PANC-1 cells more efficiently than FGF1. Therefore, FGF1/CPP-C reduced the in vitro proliferation, invasion, and migration of MIAPaCa-2 and PANC-1 cells significantly more than FGF1 through the cellular internalization of FGF1. CONCLUSION: These results suggest that the intracellular signaling mode of FGF1/CPP-C attenuates the intestinal adverse effects of C-ion radiotherapy without enhancing the malignancy of pancreatic carcinoma. Elsevier 2018-10-24 /pmc/articles/PMC6215021/ /pubmed/30406211 http://dx.doi.org/10.1016/j.ctro.2018.10.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Kawano, Mitsuko
Miura, Taichi
Fujita, Mayumi
Koike, Sachiko
Imadome, Kaori
Ishikawa, Atsuko
Yasuda, Takeshi
Imamura, Toru
Imai, Takashi
Nakayama, Fumiaki
The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title_full The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title_fullStr The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title_full_unstemmed The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title_short The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma
title_sort fgf1/cpp-c chimera protein protects against intestinal adverse effects of c-ion radiotherapy without exacerbating pancreatic carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215021/
https://www.ncbi.nlm.nih.gov/pubmed/30406211
http://dx.doi.org/10.1016/j.ctro.2018.10.004
work_keys_str_mv AT kawanomitsuko thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT miurataichi thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT fujitamayumi thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT koikesachiko thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imadomekaori thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT ishikawaatsuko thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT yasudatakeshi thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imamuratoru thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imaitakashi thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT nakayamafumiaki thefgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT kawanomitsuko fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT miurataichi fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT fujitamayumi fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT koikesachiko fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imadomekaori fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT ishikawaatsuko fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT yasudatakeshi fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imamuratoru fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT imaitakashi fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma
AT nakayamafumiaki fgf1cppcchimeraproteinprotectsagainstintestinaladverseeffectsofcionradiotherapywithoutexacerbatingpancreaticcarcinoma